The demographic and clinical features of 278 patients with genotype 1b hepatitis C virus (HCV) infection receiving daclatasvir (DCV) plus asunaprevir (ASV) therapy.</p
There are estimated to be more than a hundred million hepatitis C virus (HCV) carriers worldwide. Ab...
Background & AimsWe compared outcomes by cirrhosis status across studies of the all-oral combination...
<p>HCV viral genotype was not available for 357 individuals in the HCV mono-infection group and 74 i...
<p>Patient characteristics for 369 patients with chronic hepatitis C virus infection by HCV genotype...
HCV GT1b = hepatitis C virus genotype 1b, PrOD = paritaprevir/ritonavir/ombitasvir plus dasabuvir.</...
Daclatasvir (DCV) + asunaprevir (ASV) combination therapy has become available for patients with hep...
AIM : To assesse the efficacy and safety of therapy with daclatasvir (DCV) and asunaprevir (ASV) for...
Background & AimsDaclatasvir plus asunaprevir (DCV + ASV) has demonstrated potent antiviral activity...
Background/Aims Previous studies have reported a high rate of sustained virologic response (SVR) and...
Hepatitis C virus (HCV) chronic infection is a major causative factor for several chronic liver dise...
<p><sup>a</sup> Data were compared by Student's t-test or chi-square test as appropriate.</p><p>Clin...
PubMed ID: 30429397Purpose: Identification of hepatitis C virus (HCV) genotypes is very important in...
IMPORTANCE: The antiviral activity of all-oral, ribavirin-free, direct-acting antiviral regimens req...
<p><sup>a</sup>number of patients with known viral genotype is 56</p><p><sup>b</sup>number of patien...
The introduction of highly potent direct-acting antivirals (DAAs) has revolutionized hepatitis C vir...
There are estimated to be more than a hundred million hepatitis C virus (HCV) carriers worldwide. Ab...
Background & AimsWe compared outcomes by cirrhosis status across studies of the all-oral combination...
<p>HCV viral genotype was not available for 357 individuals in the HCV mono-infection group and 74 i...
<p>Patient characteristics for 369 patients with chronic hepatitis C virus infection by HCV genotype...
HCV GT1b = hepatitis C virus genotype 1b, PrOD = paritaprevir/ritonavir/ombitasvir plus dasabuvir.</...
Daclatasvir (DCV) + asunaprevir (ASV) combination therapy has become available for patients with hep...
AIM : To assesse the efficacy and safety of therapy with daclatasvir (DCV) and asunaprevir (ASV) for...
Background & AimsDaclatasvir plus asunaprevir (DCV + ASV) has demonstrated potent antiviral activity...
Background/Aims Previous studies have reported a high rate of sustained virologic response (SVR) and...
Hepatitis C virus (HCV) chronic infection is a major causative factor for several chronic liver dise...
<p><sup>a</sup> Data were compared by Student's t-test or chi-square test as appropriate.</p><p>Clin...
PubMed ID: 30429397Purpose: Identification of hepatitis C virus (HCV) genotypes is very important in...
IMPORTANCE: The antiviral activity of all-oral, ribavirin-free, direct-acting antiviral regimens req...
<p><sup>a</sup>number of patients with known viral genotype is 56</p><p><sup>b</sup>number of patien...
The introduction of highly potent direct-acting antivirals (DAAs) has revolutionized hepatitis C vir...
There are estimated to be more than a hundred million hepatitis C virus (HCV) carriers worldwide. Ab...
Background & AimsWe compared outcomes by cirrhosis status across studies of the all-oral combination...
<p>HCV viral genotype was not available for 357 individuals in the HCV mono-infection group and 74 i...